DRKS00010069已完成3 期
Marker-based follow-up of patients with non muscle-invasive low/intermediate risk bladder cancer - UroFollow
Forschungsstiftung Medizin am Universitätsklinikum Erlangen0 个研究点目标入组 210 人开始时间: 2016年3月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Completely resected primary or recurrent bladder cancer low/intermediate risk NMIBC pTa G1-2 with progression risk <5% within 3 years of follow-up, based on EORTC-risk-tables (Sylvester et al. 2006; http://www.eortc.be/tools/bladdercalculator); ECOG-status 0-2 (ambulatory, capable of self-care)
排除标准
- •Adjuvant BCG-therapy;
- •Concomitant bladder carcinoma in situ;
- •Tumour size >3 cm;
- •Participation in another oncological study;
- •Other cancers (except of cutaneous squamous or basal cell carcinoma) within the last 5 years;
- •Dialysis-dependent renal insufficiency
研究者
相似试验
进行中（未招募）
1 期
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical TrialsMedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850Spinal Muscular AtrophyCTIS2024-511707-42-00ovartis Pharma AG160
尚未招募
3 期
ong-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 in Clinical trialsSpinal Muscular AtrophyJPRN-jRCT2033230642Hirano Takamitsu4
进行中（未招募）
Unknown
Risk-based identification of patients with musculoskeletal pain and individualized care pathway in primary healthcare (RETAR study) – a study protocol for a benchmarking controlled trialImproving outcomes in patients with musculoskeletal painMusculoskeletal DiseasesISRCTN59800706niversity of Oulu222
招募中
1 期
Clinical observation on recurrence of non muscle invasive bladder cancer by Nourishing Yin and Clearing Sourceon muscle invasive bladder cancerITMCTR2000003747Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Shanghai University of Traditional Chinese Medicine
已完成
4 期
A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved labelNon small-cell lung carcinoma10029107lung cancerNL-OMON46049Boehringer Ingelheim34